D&D Pharmatech FAP contrast agent 2 phase begins · SD Biosensor challenges the public tuberculosis procurement market
D&D Pharmatech’s global licensing partner has begun the clinical 2 phase of an FAP-targeted contrast agent. SD Biosensor announced that it would target the global public procurement market with tuberculosis diagnostic products. Hanwha Aerospace participated in the NATO defense industry forum and expressed its intention to expand cooperation.
Get free 디앤디파마텍 email updates.
Bullstory sends one daily email when new analysis or important company news is available.
D&D Pharmatech’s global licensing partner has begun the clinical 2 phase of an FAP (fibroblast growth factor-like protein)-targeted contrast agent. This news was reported in 2026 year, 7 month, 8 day.
On the same day, D&D Pharmatech separately confirmed in a report that the 2 phase of its FAP-targeted contrast agent candidate had begun. The company said that the clinical trial was under way.
SD Biosensor announced that it would target the global public procurement market with tuberculosis diagnostic products. It plans to apply the products to public procurement and expand overseas procurement contracts.
Seoul Mayor Oh Se-hoon 2026 year 7 month 8 day said that Seoul would leap into the ranks of the world's leading cities with the goal of becoming a city where it is good to raise children. The remarks concerned the direction of city policies.
The results of a survey of small and mid-sized enterprises showed that 10 out of 8 responded that they had no dedicated legal organization or personnel. The survey shows the status of the companies' legal systems.
Hanwha Aerospace participated in the NATO defense industry forum and expressed its intention to expand cooperation at the forum. The company announced its participation in international defense cooperation.